WuXi AppTec Wuhan Site Resumes Operation

WuXi AppTec announced today that the company's Wuhan site has resumed operations, in compliance with local regulations and global COVID-19 health and safety guidelines. Operations at the Wuhan facility, which provides discovery chemistry services, will ramp up over the coming days and weeks. With this site's re-opening, WuXi AppTec has now resumed operations at all facilities in China. WuXi AppTec is taking every precaution to ensure the health and safety of its employees across every site.

Prior to the Wuhan site re-opening, WuXi AppTec leveraged the strength of its global site network and temporarily transferred operations to other sites to continue to support customers' projects. Pursuant to the robust execution of the company's business continuity plan, WuXi AppTec's multiple sites around the world have enabled the company to mitigate and minimize risk associated with unexpected work interruptions. 

"We are working with our employees and suppliers to reach steady state operations at our Wuhan site as soon as possible," said Steve Yang, Executive Vice President and Chief Business Officer of WuXi AppTec. "We value our customers' contributions to the healthcare field, and put them first by providing timely and world-class quality service and continue to do the right thing for patients – a goal that WuXi AppTec has pursued since its founding."

About WuXi AppTec

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,700 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the reproduced articles,

please email: Julia.Zhang@ubmsinoexpo.com to motify or remove the content.